HR 5461119th CongressIn Committee

Special Diabetes Program Reauthorization Act of 2025

Introduced: Sep 18, 2025

Sponsor: Rep. DeGette, Diana [D-CO-1] (D-Colorado)

Healthcare

Standard Summary

Comprehensive overview in 1-2 paragraphs

The Special Diabetes Program Reauthorization Act of 2025 extends federal funding for Special Diabetes Programs focused on Type I diabetes research and treatment. The bill authorizes $160 million annually for fiscal years 2026 through 2030, ensuring continued support for these programs over the next five years. This funding will remain available until fully expended, providing flexibility in program implementation and research initiatives aimed at preventing, treating, and potentially curing Type I diabetes.

Key Points

1Authorizes $160 million per year for Type I diabetes programs from fiscal years 2026 through 2030
2Amends Section 330B(b)(2) of the Public Health Service Act to extend existing Special Diabetes Program funding
3Funds remain available until expended, allowing for multi-year research projects and program continuity
4Represents a five-year commitment to Type I diabetes research and treatment programs
5Maintains consistent annual funding levels across all five fiscal years

Impact Areas

Type I Diabetes Patients: Continued research funding may lead to improved treatments, management tools, and potential curesMedical Research Community: Provides stable, predictable funding for diabetes research institutions and scientistsHealthcare System: Supports programs that may reduce long-term healthcare costs associated with diabetes complicationsFederal Budget: Commits $800 million in total federal spending over five years for these specialized programs

Generated by claude-sonnet-4-5-20250929 on Oct 2, 2025